The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel ( BEV-PAC ) vs bevacizumab-capecitabine ( BEV-CAP ) in HER@-negative locally recurrent/metastatic breast cancer ( LR/mBC ) .